SGC P1B22 May 2026 08:05
If the original salivary gland cancer (SGC) patients are still progression-free or still receiving AVA6000 after all this time, the significance could be very substantial clinically, strategically, and financially.
Here’s why.
1. It would massively outperform historical expectations
The benchmark you mentioned is:
* ~3.5 months median PFS.
So if AVA6000 patients are:
* 9 months,
* 12 months,
* or beyond,
that is not a marginal improvement anymore.
That becomes:
* potentially 2–4x historical disease control duration in a very difficult cancer setting.
In oncology, durability matters enormously.
A drug that keeps aggressive cancer stable for a year in heavily pretreated patients can become highly valuable even without spectacular tumour shrinkage.
⸻
2. “Median not reached” becomes extremely powerful
If enough patients remain progression-free:
* the median PFS may remain unreached for a long time.
That tells investors and oncologists:
more than half the cohort still hasn’t progressed.
In small rare-cancer studies, that can become one of the strongest efficacy signals available short of a randomized trial.
⸻
3. It would support AVA6000’s entire mechanism
AVA6000 is designed to:
* release doxorubicin preferentially in tumour tissue via FAP activation,
* while reducing systemic exposure/toxicity.
If patients are staying on drug for very long periods, that indirectly suggests:
* tolerability is holding up,
* cumulative toxicity may be lower than conventional doxorubicin,
* and patients can continue benefiting instead of stopping early due to side effects.
That is hugely important because standard doxorubicin has lifetime dose limitations due to cardiac toxicity.
If AVA6000 allows:
* prolonged exposure,
* repeated dosing,
* and sustained control,
then it validates the whole “precision chemotherapy” concept from Avacta Group plc.
⸻
4. It changes partnership and regulatory discussions
There’s a big difference between:
* “interesting early signal”
vs
* “durable disease control materially beyond historical norms.”
If mature data eventually show:
* long-tail responders,
* prolonged progression-free survival,
* ongoing treatment beyond a year,
then discussions can evolve toward:
* accelerated development,
* orphan-drug commercial potential,
* partnerships,
* or even registrational-path conversations in niche indications.
Especially because SGC is a rare cancer with high unmet need.
⸻
5. The market could begin valuing AVA6000 differently
At the moment, some investors still treat AVA6000 as:
* an early speculative oncology asset.
But if long-duration patients continue emerging, the narrative shifts toward:
* proof of biological differentiation,
* platform validation,
* and potentially broader solid tumour applicability.
That’s when valuation models can change rapidly.
Because markets often ignore early oncolog
Sign In
Follow the stocks
